Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573

CNE100002DV1

SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shenyang Xingqi Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

191.9

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+47.36%	4.62B
MERCK KGAA	+16.41%	79.16B
KYOWA KIRIN CO. LTD.	+8.35%	8.72B
YUHAN CORPORATION	+1.74%	3.82B
INDIVIOR PLC	+14.51%	2.33B
BETTA PHARMACEUTICALS CO., LTD.	-26.23%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.63%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-34.87%	2.04B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	-4.94%	1.51B

Specialty & Advanced Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
191.9 ^CNY	-2.24%		-2.79%	+47.36%

May. 22	Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	CI
Apr. 26	Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	MT

Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	May. 21	CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	Apr. 26	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%	Mar. 13	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections	Jan. 08	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index	Dec. 12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index	Dec. 12	CI
Xingqi Pharmaceutical's Diquafosol Sodium Eye Drops Bags China's Centralized Drug Bid	Nov. 08	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Xingqi Pharmaceutical Enrolls First Subject for Phase 4 Trial of Eye Drops	23-08-17	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-19	CI
Shenyang Xingqi Pharmaceutical Raises $91.5 Million From Private Share Sale	22-01-17	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd announced that it has received CNY 599.669492 million in funding from a group of investors	22-01-13	CI
Hainan Kesheng Investment Holding Co., Ltd. completed the acquisition of Shanghai Kang’ende Medical Technology Co., Ltd. from Shenyang Xingqi Pharmaceutical Co., Ltd..	21-12-29	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd completion the acquisition of the remaining 33.2% stake in Shenyang Xingqi Eye Hospital Co., Ltd. from Ningbo Meishan Bonded Port Area Zhensheng Investment Center (limited partnership).	21-11-07	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd entered into an equity transfer agreement to acquire the remaining 33.2% stake in Shenyang Xingqi Eye Hospital Co., Ltd. from Ningbo Meishan Bonded Port Area Zhensheng Investment Center (limited partnership) for approximately CNY 130 million.	21-09-29	CI
Shenyang Xingqi Pharmaceutical to Buy 33.2% Stake in Hospital	21-09-29	CI